Additionally, we screened the US FDA‐approved antitumour drugs library and identified cytarabine as a potential clinically applicable EEF2K inhibitor that has a synergistic effect with BET inhibitors on melanoma treatment. The gene discussed is EEF2K; the disease is melanoma.